Table 1.
Demographic characteristics among participants who reported pregnancy and were considered exposed to study drugs
| Characteristic | Regimen 3HP (n = 31) n (%) | Regimen 9H (n = 56) n (%) |
|---|---|---|
| Age, median (IQR) | 23 (21–30) | 25 (21–29) |
| Enrollment site | ||
| Brazil | 2 (6.9) | 1 (1.8) |
| Hong Kong | 0 (0) | 0 (0) |
| Peru | 0 (0) | 0 (0) |
| South Africa | 0 (0) | 0 (0) |
| Spain | 0 (0) | 0 (0) |
| United States/Canada | 29 (93.5) | 55 (98.2) |
| Race | ||
| American Indian/Alaskan Native | 0 (0) | 0 (0) |
| Asian/Pacific Islander | 6 (19.4) | 9 (16.1) |
| Black | 3 (9.7) | 9 (16.1) |
| Other | 1 (3.2) | 1 (1.8) |
| White | 21 (67.7) | 37 (66.1) |
| Alcohol | ||
| No | 19 (61.3) | 33 (58.9) |
| Use | 11 (35.5) | 22 (39.3) |
| Abuse | 1 (3.2) | 1 (1.8) |
| Unknown | 0 (0) | 0 (0) |
| LTBI treatment* | ||
| Contact | 19 (61.3) | 40 (71.4) |
| Fibrosis | 2 (6.5) | 1 (1.8) |
| HIV positive | 0 (0) | 1 (1.8) |
| LTBI (+) | 2 (6.5) | 0 (0) |
| TST converter | 8 (25.8) | 14 (25) |
| Education | ||
| High School | 19 (61.3) | 33 (58.9) |
| <High School | 12 (38.7) | 23 (41.1) |
| Unknown | 0 (0) | 0 (0) |
| Ethnic origin | ||
| Non–United States/Canada | 2 (6.5) | 1 (1.8) |
| United States/Canada: Hispanic | 15 (48.3) | 31 (55.4) |
| United States/Canada: non-Hispanic | 14 (45.2) | 24 (42.9) |
| HIV infection | ||
| No | 20 (64.5) | 29 (51.8) |
| Unknown | 11 (35.5) | 26 (46.4) |
| Yes | 0 (0) | 1 (1.8) |
| IDU history† | ||
| No | 31 (100) | 56 (100) |
| Yes | 0 (0) | 0 (0) |
| Unknown | 0 (0) | 0 (0) |
| Jail | ||
| No | 31 (100) | 56 (100) |
| Yes | 0 (0) | 0 (0) |
| Current smoker | ||
| No | 24 (77.4) | 47 (83.9) |
| Yes | 7 (22.6) | 9 (16.1) |
| Unemployed | ||
| No | 25 (80.6) | 51 (91.1) |
| Yes | 6 (19.4) | 5 (8.9) |
| Homeless | ||
| No | 31 (100) | 56 (100) |
| Yes | 0 (0) | 0 (0) |
Definition of abbreviations: 3HP = 12-dose once-weekly regimen of isoniazid (900 mg) plus rifapentine (900 mg); 9H = 9-month daily isoniazid (300 mg); HIV = human immunodeficiency virus; IDU = intravenous drug use; IQR = interquartile range; LTBI = latent tuberculosis infection; TST = Tuberculin Skin Test.
*
Subjects were counted only once in the order presented. The total number of HIV-infected persons who were enrolled in the study is listed separately in this table.
†
Intravenous drug use ever.